Serogroup Y Meningococcal Disease, Colombia

Agudelo, Clara Inés; Sanabria, Olga; Ovalle, María Victoria

doi:10.3201/eid1406.071357

Cited by 44 publications

(29 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Higher GMTs in response to a third dose did not increase the percentage of subjects with hSBA titers ≥1:4 against NadA or fHbp, and it is unclear whether there is any clinical benefit of higher titers in response to the OMV component. Similar results were observed at 1 month after the 2-dose schedule both in the UK among 18-24 year old university students (99-100% achieved hSBA titers ≥1:4 against fHbp, NadA and PorA1.4) [47] and among [11][12][13][14][15][16][17] year old adolescents in Canada and Australia (99-100% achieved hSBA titers ≥1:5 against fHbp and NadA; 75% achieved hSBA titers ≥1:5 against PorA1.4) [43]. At two weeks after the second vaccination, 100% of subjects in the Canada and Australia study had hSBA titers ≥1:5 against strains fHbp and NadA; the percentage of subjects with hSBA ≥1:5 against strain NZ OMV at two weeks was higher compared to 1 month after vaccination (84-96%, 64-80%, respectively) [43].…”

Section: Responses To Various Vaccination Schedulessupporting

confidence: 86%

“…kissing, sharing drinks), smoking, and sleep deprivation [11][12][13]. While incidence peaks in adolescents are common in countries like the US, Canada, and Europe, some countries in Latin America do not exhibit such a prominent peak in its adolescent population [14][15][16][17]. This observation may be in part due to differences in college/university systems where, for example, dormitory housing is more common in the US but not in Chile.…”

Section: Introductionmentioning

confidence: 83%

See 1 more Smart Citation

Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults

Nolan

O’Ryan

Wassil

et al. 2015

Vaccine

View full text Add to dashboard Cite

Vaccination programs employing capsular-based meningococcal vaccines have proved successful in a variety of settings globally since first introduced over 40 years ago. Similar successes have been demonstrated using meningococcal vaccines for use against serogroup B (MenB) outbreak strains but the diversity of MenB strains has limited vaccine use outside targeted geographic regions. MenB continues to be a significant cause of outbreaks in adolescents and young adults, as recently demonstrated in university settings in the US (Princeton, New Jersey and Santa Barbara, California) and has the potential for hyperendemic disease levels such as currently experienced in Québec and the United Kingdom. In adolescents, increased endemic disease rates and outbreak potential are likely associated with social behaviors putting individuals at risk for carriage acquisition and may explain regional and temporal variations in epidemiology. A protein-based, multi-component MenB vaccine (4CMenB) is currently licensed for use in 37 countries including EU/EEA countries, Australia, Canada, Chile, Colombia, Uruguay, and the US. In this article we review the most recent clinical trial data with 4CMenB with a focus on adolescents and young adults. The vaccine appears to have an acceptable safety profile and is well-tolerated in adolescents and young adults while providing robust, persistent levels of bactericidal antibodies considered protective for each of the four antigenic components of the vaccine. With the recent availability of this vaccine, health care providers have the first comprehensive opportunity to control meningococcal disease, a highly disruptive public health problem with a disproportionate impact on adolescents and young adults.

show abstract

Section: Responses To Various Vaccination Schedulessupporting

confidence: 86%

Section: Introductionmentioning

confidence: 83%

Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults

Nolan

O’Ryan

Wassil

et al. 2015

Vaccine

View full text Add to dashboard Cite

show abstract

“…A recent investigation reported a slight lower percentage for serogroup B distribution: 63.6% in 2010 and 51.6% in 2011, upon a characterization conducted on a total of 119 N. meningitidis strains isolated in Chile [84]. Among the other countries of Latin America, serogroup B has been predominant in Argentina [85] since 2001 and especially during the periods 1993-1995 and 2002-2005, causing about two-third of cases of infections [86], and in Colombia as resulted by the analysis performed on 434 isolates collected between 1994 and 2006 [87]. However, no data on meningitis epidemiology are available for this last country [10] and Cuba, which in 1983 experienced an outbreak caused by serogroup B wherein meningococcal disease reached the incidence of 14.4 cases per 100,000 population [88].…”

Section: Latin Americamentioning

confidence: 99%

Neisseria meningitidisinfection: who, when and where?

Gianchecchi

Torelli

Piccini

et al. 2015

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Neisseria meningitidis is a Gram-negative β-proteobacterium responsible for an endemic worldwide infection. The epidemiology and serogroup distribution can change very quickly. The incidence of meningitis infection varies from very rare to more than 1000 cases per 100,000 of the population yearly. The carriage of N. meningitidis, which represents an exclusive human commensal, is asymptomatic, but in rare cases bacteria proliferate in the CNS and rapidly lead to the death of the affected subjects. Host genetic factors, such as single nucleotide polymorphisms, can promote meningococcal disease, being able to influence the individual predisposition to the pathology. Although a reduction in meningococcal disease has been observed in Europe, a continuous surveillance is necessary to control any possible outbreaks of new hypervirulent clones into populations that could modify the epidemiology of meningococcal infections and the clinical spectrum of affected subjects.

show abstract

“…There are numerous examples for the dynamic change in serogroup distribution, e.g. in the United States [14] and Colombia [15], serogroup Y increased significantly in the last decade, whereas Canada [16], Brazil [17] and the Czech Republic [18] reported a shift to serogroup C in that period. In Saudi Arabia [19] W-135 gained dominance within only 2 years followed by other countries also observing much higher proportions of W-135 (e.g.…”

Section: Changing Epidemiologymentioning

confidence: 99%

Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region

Shibl¹,

Tufenkeji²,

Khalil

et al. 2012

JEGH

View full text Add to dashboard Cite

Facing the availability of the new generation of quadrivalent meningococcal conjugate vaccines (Menveo®, Menactra® and others pending for license) and their recent implementation in Saudi Arabia, experts from 11 countries of the Middle East region met at a "Meningococcal Leadership Forum" (MLF), which took place in May 2010 in Dubai. The participants of the conference discussed the importance of introducing the concept of conjugate vaccines - especially for children and adolescents - and elaborated a consensus recommendation to support healthcare professionals and decision makers with their expertise. In experts' opinion, conjugate vaccines are the best choice for the prevention of meningococcal disease caused by serogroups A, C, W-135 and Y. As quadrivalent meningococcal conjugate vaccines are registered and available in the Middle East region, they should replace plain polysaccharide vaccines and be integrated in pediatric and adolescent vaccination schedules, including infant vaccination concomitantly with basic EPI vaccines when licensed.

show abstract

Serogroup Y Meningococcal Disease, Colombia

Cited by 44 publications

References 3 publications

Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults

Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults

Neisseria meningitidisinfection: who, when and where?

Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region

Contact Info

Product

Resources

About